So far, Hifas da Terra has shown mushroom formulas to complement chemotherapy and radiation therapy by countering the side- effects of cancer, such as nausea, bone marrow suppression, anaemia, and lowered resistance, as well as enhancing the effectiveness of the conventional treatment. The current results and future outcomes are very promising. ihcan
• References online at ihcan-mag.com/references. About the author
PRof PERE GASCÓN, MD, PhD, is the Director of the Molecular Oncology Labs for Cellex. He holds the positions of Senior Consultant at the Division
of Medical Oncology and Scientific Coordinator of the Hematology-Oncology Department, at the Hospital Clinic of Barcelona. He specialises in molecular and translational oncology and immunology. Dr Gascón is also a Consultant for Hifas da Terra Research and Patron of their Foundation. Last year, Prof Gascón received
the ECO Foundation award for his scientific and clinical career in medical oncology. He is a global speaker on integrative oncology and one of the most internationally- recognised Spanish oncologists.
Innovative mushroom companies in Europe such as the Spanish biotech firm Hifas da Terra are finally studying new biorreactor-based culture techniques in order to maximise and standardise the composition of mushroom- based products.
It is difficult to find controlled studies comparing a group of cancer patients receiving only conventional treatment with another group that receives conventional treatment along with a Mycotherapy programme, but I believe Hifas da Terra
has already started trials with such groups, double-blind placebo control trials integrating Mycotherapy as a complementary support in cancer. In collaboration with the Translational Oncology group at University Hospital Coruña, in Galicia, Spain, effects of their formulations on cancer cells are also being studied using multicellular tumour spheroids which recreate many in vivo characteristics of the tumour and its microenvironment. This is the scope of the FungiTechOnco project supported by the European Regional Development Fund and the Spanish Centre for the Development of Industrial Technology.
In the last year, promising results show the enormous potential of medicinal mushrooms in cancer treatment. Results obtained with a combination of chemotherapy and Lentinus edodes [Shiitake] polysaccharides induced
Promising recent results
cellular and animal models”
randomised, double-blind placebo-controlled crossover study (Chiu et al, 2017).
a disease control rate of 83% and a median overall survival of 407 days in unresectable gastric cancer patients with liver metastasis (Ina et al, 2016). In addition to that, the hepatoprotective capacity of triterpenoids and polysaccharide peptides-enriched Ganoderma lucidum [Reishi] has been shown in